Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (441-450 of 567) with videos related to

Pageof 57
Sort By:
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
European Urology|December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 TrialNizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2019
Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of IsolatesMichael Feldgarden, Vyacheslav Brover, Daniel H Haft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
American Journal of Human Genetics|August 21, 2002
SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinentZahid Hassan, Viswananthan Mohan, Liaquat Ali, et al.
Antimicrobial Agents and Chemotherapy|May 10, 2017
Comparative Analysis of Extended-Spectrum-β-Lactamase CTX-M-65-Producing Salmonella enterica Serovar Infantis Isolates from Humans, Food Animals, and Retail Chickens in the United StatesHeather Tate, Jason P Folster, Chih-Hao Hsu, et al.
Cancer Immunology, Immunotherapy : CII|October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Pageof 57

Showing results (441-450 of 567) with videos related to

Sort By:
Pageof 57
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
European Urology|December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 TrialNizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2019
Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of IsolatesMichael Feldgarden, Vyacheslav Brover, Daniel H Haft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
American Journal of Human Genetics|August 21, 2002
SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinentZahid Hassan, Viswananthan Mohan, Liaquat Ali, et al.
Antimicrobial Agents and Chemotherapy|May 10, 2017
Comparative Analysis of Extended-Spectrum-β-Lactamase CTX-M-65-Producing Salmonella enterica Serovar Infantis Isolates from Humans, Food Animals, and Retail Chickens in the United StatesHeather Tate, Jason P Folster, Chih-Hao Hsu, et al.
Cancer Immunology, Immunotherapy : CII|October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Pageof 57